Literature DB >> 15733091

The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide.

Ryutaro Oba1, Akira Igarashi, Makiko Kamata, Kinya Nagata, Syoichi Takano, Hachiro Nakagawa.   

Abstract

We reported recently that angiotensin-converting enzyme (ACE) significantly degraded amyloid beta-peptide (A beta) to inhibit aggregation and cytotoxicity of A beta in PC12h cells in vitro. On the other hand, others reported that ACE had two domains with highly homologous active centres, the N-domain and C-domain, but that they differed in their characteristics such as optimum chloride ion concentration, inhibition kinetics for various ACE inhibitors and rate of hydrolysis for many substrates. The aim of this study was to determine the specific ACE domain primarily responsible for degradation of A beta. For this purpose, a series of ACE recombinant proteins, each containing only one intact domain, was constructed and expressed in COS7. Our results showed that all ACE recombinant proteins obtained were enzymatically active in terms of angiotensin I cleavage. However, inhibition of A beta aggregation and cytotoxicity of the N-domain were higher than those of the C-domain. Reverse-phase high-performance liquid chromatography analyses confirmed that the N domain degraded A beta. Our results indicate that the N domain of ACE is primarily responsible for the degradation of A beta.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15733091     DOI: 10.1111/j.1460-9568.2005.03912.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  44 in total

1.  Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.

Authors:  Matthew L Hemming; Dennis J Selkoe
Journal:  J Biol Chem       Date:  2005-09-09       Impact factor: 5.157

2.  Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.

Authors:  Linda Ferrington; Laura E Palmer; Seth Love; Karen J Horsburgh; Paul At Kelly; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2012-04-12       Impact factor: 4.060

3.  Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Linda Ferrington; J Scott Miners; Laura E Palmer; Susan M Bond; Joanne E Povey; Paul At Kelly; Seth Love; Karen J Horsburgh; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2011-02-05       Impact factor: 4.060

4.  Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein.

Authors:  Wenjun Li; Ethan Poteet; Luokun Xie; Ran Liu; Yi Wen; Shao-Hua Yang
Journal:  Brain Res       Date:  2011-03-02       Impact factor: 3.252

5.  Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes.

Authors:  Sathish Kumar; Sandesh Singh; Désirée Hinze; Michaele Josten; Hans-Georg Sahl; Martin Siepmann; Jochen Walter
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 6.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

7.  Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme.

Authors:  Kun Zou; Tomoji Maeda; Atsushi Watanabe; Junjun Liu; Shuyu Liu; Ryutaro Oba; Yoh-ichi Satoh; Hiroto Komano; Makoto Michikawa
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

8.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

9.  Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease.

Authors:  Nofar Torika; Keren Asraf; Ella Roasso; Abraham Danon; Sigal Fleisher-Berkovich
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

Review 10.  Do angiotensin receptor blockers protect against Alzheimer's disease?

Authors:  Hitomi Kurinami; Munehisa Shimamura; Naoyuki Sato; Hironori Nakagami; Ryuichi Morishita
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.